Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 ...

Utrecht-based Merus is banking $40 million upfront from the deal, and getting a $20 million equity investment, but the total value could go north of $1.6 billion.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company ...

Merus N.V. announced that an abstract for petosemtamab combined with pembrolizumab as a first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has been ...

O n Friday, Wells Fargo (NYSE:WFC) initiated coverage on Merus N.V. (NASDAQ:MRUS), currently trading at $41.54 with a market capitalization of $2.84 billion, with an Overweight rating and a price ...

Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million for the quarter, compared to the consensus estimate of $10.57 million.